Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Venetoclax and ibrutinib therapy shows favourable results in the treatment of R/R chronic lymphocytic leukaemia

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL

Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL

Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma

Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction